What is Zacks Research’s Forecast for ESLA FY2026 Earnings?

Estrella Immunopharma, Inc. (NASDAQ:ESLA) – Equities research analysts at Zacks Research lifted their FY2026 earnings per share (EPS) estimates for shares of Estrella Immunopharma in a report issued on Wednesday, August 26th. Zacks Research analyst D. Bautz now anticipates that the company will post earnings of ($0.25) per share for the year, up from their previous estimate of ($0.29). The consensus estimate for Estrella Immunopharma’s current full-year earnings is ($0.29) per share.

Estrella Immunopharma (NASDAQ:ESLA) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.04.

Separately, Weiss Ratings upgraded shares of Estrella Immunopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 25th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Estrella Immunopharma currently has a consensus rating of “Hold” and an average price target of $8.00.

Estrella Immunopharma Trading Down 4.6%

Shares of Estrella Immunopharma stock opened at $0.69 on Wednesday. The firm has a fifty day simple moving average of $0.81 and a 200-day simple moving average of $1.09. The stock has a market capitalization of $30.08 million, a price-to-earnings ratio of -2.88 and a beta of 0.88. Estrella Immunopharma has a 1-year low of $0.63 and a 1-year high of $3.15.

Institutional Investors Weigh In On Estrella Immunopharma

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Quadrature Capital Ltd acquired a new position in Estrella Immunopharma during the 4th quarter valued at $43,000. State Street Corp increased its holdings in shares of Estrella Immunopharma by 93.5% during the 4th quarter. State Street Corp now owns 43,252 shares of the company’s stock worth $67,000 after purchasing an additional 20,900 shares during the period. XTX Topco Ltd raised its holdings in Estrella Immunopharma by 376.9% in the 4th quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock valued at $77,000 after acquiring an additional 39,099 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of Estrella Immunopharma in the 2nd quarter valued at $54,000. Finally, Marshall Wace LLP bought a new stake in Estrella Immunopharma during the 4th quarter worth approximately $88,000. Institutional investors and hedge funds own 0.35% of the company’s stock.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.